Opendata, web and dolomites

GAF SIGNED

The First non-cancerogenic Glyoxal Acid-Free fixative for a Formalin-free hospital

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GAF project word cloud

Explore the words cloud of the GAF project. It provides you a very rough idea of what is the project "GAF" about.

off    august    glyoxal    outsourcing    cros    introducing    producers    2017    chemical    preserving    investments    serve    founders    business    substance    retain    primarily    veterinary    acid    performing    labs    laboratories    scenario    market    spin    healthcare    segment    entities    services    patient    structural    prohibited    finance    specimens    forensic    union    huge    fixation    scientific    cancerogenic    tissue    capacity    emergency    combined    innovative    preserve    alternative    model    community    initially    first    free    customers    reagent    guarantee    pathological    represented    optimal    formalin    hospitals    torino    diagnostic    solution    time    diagnosis    phases    pathology    pharmaceutical    gaf    academic    biosciences    updated    agreements    clinics    proposes    toxicity    born    valid    institutes    commercialization    medical    plan    public    university    private    correct    absence    feasibility    replace    second    accepted    proof    validate    clients    tissues    fixative    faster    addressable    therapy    company    carcinogenic    quality    addax    formaldehyde    molecular   

Project "GAF" data sheet

The following table provides information about the project.

Coordinator
ADDAX BIOSCIENCES SRL 

Organization address
address: STRADA MONTGRENO 247
city: TORINO
postcode: 10123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADDAX BIOSCIENCES SRL IT (TORINO) coordinator 50˙000.00

Map

 Project objective

ADDAX Biosciences is an academic spin-off of the University of Torino, born after long time research activity of its founders on the pathological tissues. Our company goal is to replace the use of Formalin (a cancerogenic solution of formaldehyde) as fixative, while preserving optimal tissue fixation to guarantee correct diagnosis and therapy. In the European Union, Formaldehyde is recognized as a carcinogenic substance, and its use, production and commercialization is prohibited from August 2017. However, at present there is no valid alternative to Formalin accepted by the scientific community to preserve patient specimens. Our project proposes a huge step forward in the fixative market by introducing an innovative reagent, based on acid-free Glyoxal (GAF), that will allow the optimal tissue fixation at structural and molecular level, combined with the absence of toxicity and carcinogenic activity. The addressable market of our GAF product is primarily represented by the healthcare segment, thus the targeted users and clients are public and private entities performing pathology services, such as: Hospitals, Clinics, Emergency Medical Services, Diagnostic Laboratories, Academic Institutes, Forensic Laboratories, CROs, Veterinary Clinics, Labs and Hospitals. Our business model is initially based in two distinct phases: the first one aimed to achieve a controlled production capacity to serve the first customers and finance the further investments; in the second phase, from second year, we expect a faster scale-up through outsourcing production agreements with major European producers of chemical and pharmaceutical products. In this scenario, Addax will retain the R&D, quality, scientific and market development. The objectives of our Feasibility Study are to validate at European level our proof-of-concept and design an updated Business Plan and Commercialization Plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More